Robert L Van Nostrand
CIK 1225198 · last filed 2026-01-09
Robert L Van Nostrand is a corporate insider who has filed 138 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for SLS, was dated Jan 9, 2026. Across all open-market trades the lifetime net is −$5.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $993.1K across reported positions. 12 SEC filings were submitted jointly with Galena Biopharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ITCI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
300 GEORGE STREET
NEW HAVEN, CT 06511
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SLS | Director | 82,900 | $11.98 | $993.1K | $14.8K | 11 | 2026-01-09 |
| Intra-Cellular Therapies, Inc. (ITCI) Delisted | Director | 0 | $131.87 | $0 | -$5.32M | 59 | 2025-04-02 |
| YIELD10 BIOSCIENCE, INC. (YTEN) Delisted | Director | 2,026 | $0.35 | $709 | $0 | 34 | 2024-04-01 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Director | 0 | — | — | $0 | 13 | 2020-01-29 |
| YIELD10 BIOSCIENCE, INC. (MBLX) Delisted | Director | 31,250 | — | — | $21.4K | 11 | 2015-09-14 |
| ACHILLION PHARMACEUTICALS INC (TPTX) Delisted | Director | — | $76.01 | — | $0 | 4 | 2008-12-17 |
Recent Filings
138 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-09 | SLS | Grant (A) | +50,000 | $0 | EDGAR |
| 2025-06-13 | SLS | Buy (P) | +10,000 | $14.8K | EDGAR |
| 2025-04-02 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Disp (D) | −11,340 | -$1.50M | EDGAR |
| 2025-01-14 | SLS | Grant (A) | +12,500 | $0 | EDGAR |
| 2024-07-02 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | +83 | $5.7K | EDGAR |
| 2024-06-25 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Exer (M) | +1,567 | $0 | EDGAR |
| 2024-06-21 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Mixed | — | -$1.18M | EDGAR |
| 2024-06-18 | — | Notice (144) | −20,000 | -$1.52M | EDGAR |
| 2024-06-18 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-02 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | +79 | $5.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.